

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER**

Applicants : Lundgren et al.
 Serial No. : 10/687,540
 Filing or 371(c) Date : October 15, 2003
 For : IMPROVED STABILITY FOR INJECTION
 SOLUTIONS
 Examiner : C. Azpuru
 Group Art Unit : 1615

JUN 08 2005**Certificate of Transmission Under 37 C.F.R. 1.8**

I hereby certify that this paper is being facsimile
 transmitted to the U.S. Patent and Trademark Office
 on the date indicated below at the facsimile number
1-703-872-9306.

John M. Genova

32,224

Attorney Name

PTO Reg. No.



Signature

Date of Signature

RECEIVED
JUN -9 2005
OIPE/JCWS

Mail Stop Amendment
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Attn: Examiner Carlos A. Azpuru
Facsimile: 1-703-872-9306
Pages: 2 pages total

TERMINAL DISCLAIMER

Sir:

AstraZeneca AB, a corporation created and existing under the laws of Sweden, and having a business address at S-151 85 Södertälje, Sweden, hereby through its undersigned agent, who is empowered to act on behalf of AstraZeneca AB, represents that AstraZeneca AB is the owner of the entire right, title and interest of the above-identified patent application Serial No. 10/687,540, by Assignment recorded on March 22, 2001 at Reel 01160, Frame 0081.

AstraZeneca AB, by its undersigned agent, states that all evidentiary documents have been reviewed and certifies that, to the best of its knowledge and belief, title to Application Serial No. 10/687,540 and US 6,660,279 is in AstraZeneca AB. The inventions claimed in Application Serial No. 10/687,540 and US 6,660,279 were commonly owned by AstraZeneca AB at the time the later invention was made.

| 06/09/2005 TL0111 00000029 231703 10687540
 | 01 FC:1814 130.00 DA

AstraZeneca AB hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,660,279 as presently shortened by any terminal disclaimer. AstraZeneca AB hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period it and US 6,660,279 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,660,279, as presently shortened by terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization is hereby given to charge Deposit Account No. 23-1703 in the amount of One Hundred and Thirty Dollars (\$130.00) to cover the fee as required by 37 C.F.R. §1.20(d) and for any other fee that may be required in connection with this communication.

Dated: June 8, 2005

Respectfully submitted,



John M. Genova

Reg. No. 32,224

Attorney Direct Dial (212) 819-8832

Client No. 007470
White & Case, LLP